ds-3939a
Metastatic Solid Tumor
Daiichi SankyoPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 65/ 100
Competitive context
131 Active assets in the Metastatic Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin InSilico Medicine Hong Kong Limited | Phase 2 | CCC |
Pembrolizumab InSilico Medicine Hong Kong Limited | Phase 2 | CCC |
Cyclophosphamide InSilico Medicine Hong Kong Limited | Phase 2 | CCC |
Nivolumab Lantern Pharma Inc. | Phase 2 | CCC |
Trastuzumab Emtansine M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
ds-3939a is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →